Previous 10 | Next 10 |
Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities PR Newswire Announces encouraging secondary endpoint results from NIH-sponsored Phase 2 clinical trial of Bryostatin-1 in advanced Alzheimer's disease patients Maintains strong finan...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Clinical-stage biopharmaceutical firm Synaptogenix (NASDAQ: SNPX ) demonstrated the harsh pitfalls associated with innovative medicine. Following the disclosure of disappointing results for its Phase 2 study involving the t...
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease PR Newswire NEW YORK , Dec. 16, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an eme...
Summary Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in Alzheimer’s disease for the current quarter. Preclinical work showed that its drug candidate Bryostatin-1 has some effect, and has a unique mechanism of action. Despite a clear po...
Synaptogenix Announces $15 Million Private Placement with Existing Investors PR Newswire Topline data from NIH-supported Phase 2 clinical trial for advanced AD patients expected during the current quarter NEW YORK , Nov. 18, 2022 /PRNewswire/ -- S...
Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022 PR Newswire Synaptogenix is one of few companies developing therapeutics for advanced Alzheimer's disease (AD); no such drug has received FDA approval to date Topline data from NIH...
Synaptogenix Welcomes Lecanemab Phase 3 Trial Results PR Newswire Synaptogenix expecting data from its Phase 2 clinical trial of Bryostatin-1 for advanced Alzheimer's disease in fourth quarter 2022 NEW YORK , Sept. 28, 2022 /PRNewswire/ -- Synapto...
Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data PR Newswire Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK , July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ...
Synaptogenix Announces Corporate Update Conference Call PR Newswire NEW YORK , July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegene...
Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data PR Newswire Dose optimization prepares the Company for its next phase of Bryostatin clinical development Company...
News, Short Squeeze, Breakout and More Instantly...
Synaptogenix Inc. Company Name:
SNPX Stock Symbol:
OTCMKTS Market:
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis PR Newswire Collaborative study will evaluate drug's potential to improve synaptic health and cognitive function in MS patients NEW YORK , ...
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery PR Newswire Proposed Schedule III drug classification expected to de-risk Cannasoul's cannabis research and potential regulatory pathways ...